Peginterferon alfa2a
Sponsors
University Hospital, Bordeaux, University of Chicago, sigma-tau i.f.r. S.p.A., Third Affiliated Hospital, Sun Yat-Sen University
Conditions
Chronic Hepatitis CHIV InfectionsHepatitis CHepatitis C VirusHepatitis C, ChronicTreatment Failure
Phase 2
Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients
CompletedNCT00221650
Start: 2002-04-30End: 2004-06-30Updated: 2007-06-13
A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C
WithdrawnNCT00814606
Start: 2010-02-28End: 2010-10-31Updated: 2013-07-01
Phase 3
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
CompletedNCT01178996
Start: 2004-12-31End: 2009-07-31Updated: 2010-08-10
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients
CompletedNCT01263860
Start: 2010-12-31End: 2014-06-30Updated: 2014-11-18
Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6
CompletedNCT01433887
Start: 2011-11-30End: 2014-06-30Updated: 2014-11-18
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism
NCT01441804
Start: 2011-05-31End: 2014-08-31Target: 200Updated: 2013-10-01